ASCO: Heat Shock Protein 90 Inhibitor Shows Promise in NSCLC

Results from the GALAXY-1 trial showed that the novel second-generation heat shock protein 90 (HSP90) inhibitor ganetespib could potentially improve survival in patients with advanced-stage non–small-cell lung cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news